PHEX Protein in the Parathyroid Gland Contributes to Phosphate Sensing
- 13 June 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , e1-e8
Abstract
Context: Loss-of-function variants in the PHEX gene cause X-linked hypophosphatemia (XLH) with inappropriate secretion of fibroblast growth factor 23. The PHEX protein is therefore predicted to be involved in the phosphate (Pi)-sensing mechanism in mature osteocytes. The parathyroid glands sense short-term fluctuations in serum Pi levels and secrete PTH accordingly. However, the precise mechanisms for Pi sensing in the parathyroid gland have not been elucidated. Objective: To clarify the involvement of PHEX in phosphate sensing in the parathyroid glands, PTH reactions after Pi loading were retrospectively compared between patients with XLH and those with tumor-induced osteomalacia (TIO). Methods: Serum Pi, intact PTH (iPTH) and albumin-corrected serum calcium (cCa) levels at 1 hour after oral phosphate administration at doses ranging from 300 to 1500 mg were analyzed. The trend of iPTH in each participant was compared between XLH and TIO. Results: Six XLH patients and 13 TIO patients were included. The serum Pi level significantly increased after the oral Pi load, whereas the serum cCa level was stable. The slope of the scatter plot of iPTH (pg/mL) vs Pi (mg/dL) after the oral Pi load for each patient was 41.4 (median) in XLH, which was significantly greater than the 7.1 in TIO (P = .034). Conclusion: iPTH increased in accordance with Pi levels, with a greater slope observed in XLH than in TIO after oral Pi loading. This finding suggests that PHEX in the parathyroid glands might also determine the serum Pi-sensing threshold and mediate PTH secretion in the case of abrupt fluctuations in serum Pi levels, which may explain the high prevalence of secondary and tertiary hyperparathyroidism in patients with XLH.Keywords
Funding Information
- JSPS KAKENHI (JP21K09293)
- Kyowa Kirin Co., Ltd
This publication has 26 references indexed in Scilit:
- Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23Journal of Bone and Mineral Metabolism, 2021
- Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective SurveillanceJournal of Bone and Mineral Research, 2020
- Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced OsteomalaciaJournal of Bone and Mineral Research, 2020
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary AnalysisJournal of Bone and Mineral Research, 2018
- Extracellular Phosphate Induces the Expression of Dentin Matrix Protein 1 Through the FGF Receptor in OsteoblastsJournal of Cellular Biochemistry, 2017
- Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine SocietyJournal of Bone and Mineral Metabolism, 2015
- Identification of a novelFN1-FGFR1genetic fusion as a frequent event in phosphaturic mesenchymal tumourThe Journal of Pathology, 2014
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011
- Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humansJournal of Bone and Mineral Metabolism, 2007
- PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemiaPediatric Nephrology, 1999